Imexpharm Joint Stock Pharmaceutical Company (IMP-HOSE) announces the confirmation of information regarding the transfer of IMP shares by a major shareholder.
Specifically, on May 22, 2025, IMP received information that Lian SGP Holding Pte. Ltd., a company established in Singapore and wholly owned by Livzon Pharmaceutical Group Inc. (a company established in China), has signed a framework agreement with SK Investment Vina III Pte. Ltd., Sunrise Kim Investment JSC, and KBA Investment JSC regarding the acquisition of shares in Imexpharm Pharmaceutical Joint Stock Company.
Accordingly, Lian SGP Holding Pte. Ltd. is expected to execute the share purchase transaction at Imexpharm, acquiring 47.69% of the shares owned by SK Investment Vina III Pte. Ltd., 9.75% of the shares owned by Sunrise Kim Investment JSC, and 7.37% of the shares owned by KBA Investment JSC. The total expected share transfer ratio is 64.81% of Imexpharm’s charter capital.
According to the 2024 Annual Report, these three shareholders hold 99,839,000 IMP shares – with SK Investment owning 73.4 million IMP shares, Binh Minh Kim holding 15 million IMP shares, and KBA Investment possessing 11.3 million IMP shares.
Closing the session on May 23, the IMP share price increased by 2.77% to VND 52,000/share. The deal value is estimated at nearly VND 5,192 billion.
IMP stated that the above information was provided by the company’s major shareholder, SK Investment Vina III Pte., and was disclosed by Livzon Pharmaceutical Group Inc. on the official website of the Hong Kong Stock Exchange (HKEX) and the Shenzhen Stock Exchange (SZSE).
Therefore, IMP confirms the receipt of the above information and will continue to monitor the transaction and promptly disclose information to the State Securities Commission, the Ho Chi Minh City Stock Exchange, and investors in accordance with regulations.
It is known that IMP successfully organized the 2025 Annual General Meeting of Shareholders on April 25, 2025. At the meeting, shareholders of IMP inquired about the news circulating in the media regarding SK’s search for investors to divest from IMP and asked about the potential impact on the company’s development strategy and business operations.
The company’s management board reassured that, thanks to the close cooperation with SK, Imexpharm has established a solid position in the industry, backed by enhanced capabilities, a global network, and a dedicated and professional team. Hence, even in the event of SK’s future divestment, the company believes that Imexpharm will continue to grow independently and sustainably.
Previously, the IMP Board of Directors approved the deployment of the “Cat Khanh Pharmaceutical Factory Complex – Imexpharm Pharmaceutical Joint Stock Company” with IMP as the investor. The objective is to diversify the product portfolio to meet the domestic market demand, increase revenue and profits for the company in line with its strategy to meet export market expansion goals.
The project has a total area of 97,602.1 m2 and is located in the Quang Khanh Industrial Cluster (phase 1), My Tra town, Cao Lanh city, and An Binh ward, Cao Lanh district, Dong Thap province. The designed capacity is expected to be an average of 1.4 billion units/year from the completion and full operation of the project. The factory standard is WHO-GMP/EU-GMP. The total investment capital of the project is VND 1,495 billion, sourced from owner’s equity and loans from shareholders and/or credit institutions and/or other legal capital mobilization channels. The minimum payback period is 7 years.
The project’s duration is 50 years from the date of being granted the investment registration certificate, but it shall not exceed the land lease term as prescribed by law.
According to IMP, the expected project implementation progress includes: land rent payment and land receipt completed in March 2025; legal procedures completed by September 2025; construction commencement in the fourth quarter of 2025, and operation: 2028 – 2030.
However, IMP also stated that this progress may differ from the plan due to the impact of provincial/municipal mergers and changes in administrative management units.
The Road Less Traveled: Revitalizing a Forgotten Highway with a $230 Million Investment
The project, categorized as a Group B initiative, boasts a substantial investment of nearly VND 540 billion, funded by the central government and Danang City. With a timeline set from 2025 to 2028, this endeavor promises significant impact and transformation.
“High-Speed Dreams: Reshaping Lam Dong with a Highway Resettlement Project”
Let me know if you would like me to tweak it or provide other options!
The construction of the Tan Phu – Bao Loc and Bao Loc – Lien Khuong highway road project’s resettlement areas will be undertaken this year.
“Vietnam: A Strategic Market, Captivating US Businesses.”
U.S. Secretary of Commerce, Howard Lutnick, commended Vietnam’s efforts and goodwill in negotiating the bilateral trade agreement. He emphasized, “Vietnam is an important and attractive market for American businesses.”
“Malaysian Businesses: Strengthen Your Bond with Vietnam, Says Prime Minister”
On the morning of May 25, during his working visit to Malaysia, Prime Minister Pham Minh Chinh attended the “Meet Vietnam – Malaysia Businesses” program, organized by the Ministry of Finance of Vietnam in collaboration with the Embassy of Vietnam in Malaysia and the Malaysia Chamber of Commerce and Industry.
“Traphaco Confirms Date for 2024 Second Dividend Payment”
Traphaco has announced that June 16th is the last day for shareholders to register to receive the second round of cash dividends for 2024, with a payout ratio of 20%. This round of dividends will cost the company approximately VND 82.9 billion.
